Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goda Choi

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Blood|April 24, 2024
Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMTJaime Sanz, Myriam Labopin, Goda Choi, et al.
Leukemia|November 1, 2024
Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemiaAvichai Shimoni, Christophe Peczynski, Myriam Labopin, et al.
Blood Advances|October 11, 2022
Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control studyCarin L E Hazenberg, Aniek O de Graaf, René Mulder, et al.
Bone Marrow Transplantation|September 7, 2022
Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMTAlexandros Spyridonidis, Myriam Labopin, Eolia Brissot, et al.
Leukemia|July 24, 2024
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamideSimona Piemontese, Myriam Labopin, Goda Choi, et al.
Hemasphere|December 12, 2024
Time-restricted versus standard-duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON-96 trialAnnoek E C Broers, Ellen Meijer, Bronno van der Holt, et al.
Molecular Medicine (Cambridge, Mass.)|January 5, 2011
Acute stress elicited by bungee jumping suppresses human innate immunityDavid J van Westerloo, Goda Choi, Ester C Löwenberg, et al.
American Journal of Hematology|May 30, 2025
Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWPAli Bazarbachi, Jacques-Emmanuel Galimard, Iman Abou Dalle, et al.
American Journal of Hematology|June 10, 2024
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Cancer Medicine|January 20, 2022
Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemiaRama Al Hamed, Myriam Labopin, Etienne Daguindau, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Blood|April 24, 2024
Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMTJaime Sanz, Myriam Labopin, Goda Choi, et al.
Leukemia|November 1, 2024
Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemiaAvichai Shimoni, Christophe Peczynski, Myriam Labopin, et al.
Blood Advances|October 11, 2022
Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control studyCarin L E Hazenberg, Aniek O de Graaf, René Mulder, et al.
Bone Marrow Transplantation|September 7, 2022
Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMTAlexandros Spyridonidis, Myriam Labopin, Eolia Brissot, et al.
Leukemia|July 24, 2024
Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamideSimona Piemontese, Myriam Labopin, Goda Choi, et al.
Hemasphere|December 12, 2024
Time-restricted versus standard-duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON-96 trialAnnoek E C Broers, Ellen Meijer, Bronno van der Holt, et al.
Molecular Medicine (Cambridge, Mass.)|January 5, 2011
Acute stress elicited by bungee jumping suppresses human innate immunityDavid J van Westerloo, Goda Choi, Ester C Löwenberg, et al.
American Journal of Hematology|May 30, 2025
Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWPAli Bazarbachi, Jacques-Emmanuel Galimard, Iman Abou Dalle, et al.
American Journal of Hematology|June 10, 2024
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Cancer Medicine|January 20, 2022
Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemiaRama Al Hamed, Myriam Labopin, Etienne Daguindau, et al.
Pageof 7